Understanding why some patients don't respond to CAR T cell therapy
Mechanisms of treatment failure in chimeric antigen receptor T cell therapy
['FUNDING_R01'] · FRED HUTCHINSON CANCER CENTER · NIH-10640839
This study is looking into why some patients with relapsed non-Hodgkin lymphoma don’t respond well to CAR T cell therapy, by examining their tumors and immune cells before and after treatment to find clues that could help improve future therapies.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | FRED HUTCHINSON CANCER CENTER (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-10640839 on ClinicalTrials.gov |
What this research studies
This research investigates the reasons behind treatment failures in patients receiving chimeric antigen receptor (CAR) T cell therapy for relapsed non-Hodgkin lymphoma. By analyzing tumor biopsies and patient T cells before and after treatment, the study aims to identify biological characteristics that predict treatment response and understand how tumors adapt to evade the immune response. Advanced techniques like flow cytometry and single-cell RNA sequencing will be utilized to gather detailed insights into the tumor microenvironment and immune interactions.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with relapsed or refractory B-cell non-Hodgkin lymphoma who are undergoing CAR T cell therapy.
Not a fit: Patients with other types of cancers or those who are not eligible for CAR T cell therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies and better outcomes for patients undergoing CAR T cell therapy.
How similar studies have performed: Previous research has shown promise in understanding treatment resistance in CAR T cell therapy, but this specific approach is novel in its comprehensive evaluation of tumor biology and immune interactions.
Where this research is happening
SEATTLE, UNITED STATES
- FRED HUTCHINSON CANCER CENTER — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: TILL, BRIAN — FRED HUTCHINSON CANCER CENTER
- Study coordinator: TILL, BRIAN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.